Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modification of pre-mRNA processing: application to dystrophin expression.

Steve D Wilton1, Susan Fletcher

  • 1Centre for Neuromuscular and Neurological Disorders, QE II Medical Centre, Nedlands, WA 6009, Australia. swilton@cyllene.uwa.edu.au

Current Opinion in Molecular Therapeutics
|April 14, 2006
PubMed
Summary

Antisense oligonucleotides offer a promising therapy for Duchenne muscular dystrophy by targeting pre-mRNA to correct dystrophin gene mutations. Clinical trials are anticipated, focusing on exon skipping to restore protein function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding the toolbox: Emerging antisense oligonucleotide mechanisms for modulating gene expression.

Molecular therapy. Nucleic acids·2026
Same author

Structured Online Support to Inform and Assist Antidepressant Deprescribing in Primary Care: Protocol for a Pragmatic, Randomized Controlled Trial (The WiserAD Trial).

JMIR research protocols·2026
Same author

A severe neurodevelopmental syndrome linked to a South Asian founder variant in the UFMylation adaptor CDK5RAP3.

Acta neuropathologica·2026
Same author

Paraspeckle condensation is controlled via TDP-43 polymerization and linked to neuroprotection.

Nature cell biology·2026
Same author

Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy.

Nature neuroscience·2025
Same author

Skipping of Duplicated Dystrophin Exons: In Vitro Induction and Assessment.

Methods in molecular biology (Clifton, N.J.)·2025

Area of Science:

  • Molecular Biology
  • Genetics
  • Therapeutics

Background:

  • Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene.
  • The large size and complexity of the dystrophin gene present therapeutic challenges.
  • Antisense oligonucleotides (ASOs) are a novel therapeutic approach for genetic disorders.

Purpose of the Study:

  • To review the development of antisense oligonucleotides for Duchenne muscular dystrophy.
  • To discuss the potential of targeted exon skipping in pre-mRNA processing.
  • To explore challenges and future directions for ASO therapy in DMD.

Main Methods:

  • Review of scientific literature and preclinical studies.
  • Analysis of antisense oligonucleotide design for dystrophin gene targeting.

Related Experiment Videos

  • Discussion of exon skipping mechanisms in pre-mRNA splicing.

    • Main Results:

    • Antisense oligonucleotides can be designed to induce targeted exon skipping.
    • Exon skipping can correct reading frame disruptions caused by dystrophin gene mutations.
    • This approach holds promise for restoring dystrophin protein expression.

    Conclusions:

    • Targeted exon skipping using antisense oligonucleotides is a viable strategy for DMD.
    • Upcoming clinical trials in 2006 will assess the safety and efficacy of this therapy.
    • Challenges remain in optimizing delivery and ensuring long-term therapeutic benefits.